Details for New Drug Application (NDA): 202379

✉ Email this page to a colleague

NDA 202379 describes ZYTIGA, which is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. Additional details are available on the ZYTIGA profile page.

The generic ingredient in ZYTIGA is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.

Summary for 202379

Tradename:	ZYTIGA
Applicant:	Janssen Biotech
Ingredient:	abiraterone acetate
Patents:	0

Pharmacology for NDA: 202379

Mechanism of Action	Cytochrome P450 17A1 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors

Medical Subject Heading (MeSH) Categories for 202379

Antineoplastic Agents
Cytochrome P-450 Enzyme Inhibitors
Steroid Synthesis Inhibitors

Suppliers and Packaging for NDA: 202379

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ZYTIGA	abiraterone acetate	TABLET;ORAL	202379	NDA	Janssen Biotech, Inc.	57894-150	57894-150-12	120 TABLET in 1 BOTTLE (57894-150-12)
ZYTIGA	abiraterone acetate	TABLET;ORAL	202379	NDA	Janssen Biotech, Inc.	57894-195	57894-195-06	60 TABLET, FILM COATED in 1 BOTTLE (57894-195-06)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	250MG
Approval Date:	Apr 28, 2011	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	500MG
Approval Date:	Apr 14, 2017	TE:	AB	RLD:	Yes

Expired US Patents for NDA 202379

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-001	Apr 28, 2011	5,604,213	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.